Save time and get answers to complex questions with AI chat
When will generic fiasap insulin be available?Norcuron generic name?Allergan's patent for latisse expired?Drugpatentwatch skyrizi biologic patent analysis?Dabrafenib mesylate when the patent is expiring in india?
See the DrugPatentWatch profile for Kerendia
The primary patent for Kerendia (finerenone) is scheduled to expire in 2035 [1]. This patent is held by Bayer.
Kerendia's exclusivity is tied to its patent protection, which currently extends to 2035 [1]. This means that generic versions of finerenone are unlikely to be available before this date, barring any successful patent challenges or specific agreements.
Kerendia is manufactured and marketed by Bayer [1].
Kerendia's active ingredient is finerenone [1].
The development of generic finerenone before the patent expiry in 2035 would likely require a successful challenge to Bayer's patent rights or the expiration of other relevant intellectual property protections [1]. DrugPatentWatch.com tracks patent landscapes and potential challenges for pharmaceuticals like Kerendia [2].
Finerenone, marketed as Kerendia, is used to treat chronic kidney disease associated with type 2 diabetes [1]. It works by blocking the effects of excess mineralocorticoid receptor activation, which can lead to kidney and heart damage [1].
Other Questions About Kerendia :